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etc. The unit of measurement was cost per successful treatment. Differences in costs 
and efﬁ cacy rates were analyzed by the appropriate statistical tools. The study was 
performed from a government’s perspective. RESULTS: A total of 44 patients were 
evenly randomised to receive LNG-IUS treatment and TBEA and evaluation was
performed 1 year after treatment. Of these, 18 patients from the LNG-IUS group 
completed the study with 3 dropouts. Ten achieved menorrhagic control and 5 had
to be converted to other therapies. In patients receiving TBEA therapy, 7 dropped
out and 15 were deemed successful. The overall cost of treatment for LNG-IUS and 
TBEA groups was HKD140,000 (USD18,000; 1USD  7.8HKD) and HKD430,000 
(USD55,000) respectively. The average cost per successful treatment per patient was 
therefore HKD14,000 (USD1,800) and HKD28,600 (USD3,660) for the LNG-IUS and 
TBEA patients respectively. CONCLUSIONS: From this small group of patients
enrolled in a clinical trial to assess the outcomes of LNG-IUS and TBEA, it appears 
that the LNG-IUS therapy is more cost-effective. The major cost drivers appear to be 
the procedural and hospitalization costs arising from TBEA.
PIH17
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OBJECTIVES: To evaluate the costs and effectiveness of the conventional drug treat-
ment with clomiphene citrate versus anastrozole in the induction of the ovulation in 
infertile adult patients attending a Mexican public hospital. METHODS: A prospec-
tive and descriptive clinical pilot study was conducted in a Mexican public hospital 
“La Raza” of the Mexican Social Security Institute (IMSS). Thirty adult patients with
infertility due to anovulation were recruited and grouped into two groups. Group A
was treated with clomiphene citrate and group B with anastrozole for 6 months. A 
systematic scientiﬁ c review of the published literature related with the two drugs was 
done, in order to gather the drug efﬁ cacy and adverse effects probabilities. The drug 
efﬁ cacies gathered in the Mexican clinical pilot study and the efﬁ cacy data from the
literature review were analyzed by means of meta-analysis. The direct medical and 
non direct medical costs as well as the indirect costs were assessed using a micro-
costing process. Using the Mexican women epidemiological data a hypothetic popula-
tion of 10000 was considered. A time horizon of one year was estimated. The
Markov-Montecarlo model-computarized TreeAge Program was used in order to 
evaluate the cost-effectiveness (CE) ratio. The discount rate, incremental and marginal
analyses were done. RESULTS: The meta-analysis odds ratio was 0.85 for the ovula-
tion induction and 1.46 for pregnancy. The most CE treatment was clomiphene citrate
with a ratio of $173 dollars/QALY versus $192 of anastrozole. The result of the
incremental analysis was $18 dollars/QALY. CONCLUSIONS: The conventional drug
treatment (clomiphene) is the most cost/effective for the present study population. 
Further investigations are needed in order to assess the costs of adverse events in order
to obtain conclusive data.
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OBJECTIVES: To estimate the expected health beneﬁ ts, costs and incremental cost-
effectiveness ratio of routine vaccination with the new 10-valent pneumococcal non-
typeable haemophilus inﬂ uenzae protein-D conjugate vaccine (PHiD-CV) compared 
with no vaccination and the currently available 7-valent pneumococcal conjugate
vaccine (PCV-7) in Sweden. METHODS: A cross-sectional population model was used 
to estimate the impact of vaccination over 1-year at vaccine steady-state and to
perform an incremental cost-effectiveness analysis, comparing 3 different vaccination
strategies. The base-case analysis was performed from a societal perspective, using a
3 dose (2  1) vaccination schedule. The effects of herd-protection, serotype replace-
ment and serotype cross-protection were calculated separately. The main outcomes 
were measured by reduction in the disease burden, costs, QALYs and incremental
cost-effectiveness ratio (ICER) per QALY gained. Sensitivity analyses were performed 
to evaluate the robustness of the model. RESULTS: Preliminary results indicate that
PHiD-CV could prevent a considerable number of pneumococcal infections- particu-
larly acute otitis media. Annual health care costs (vaccine costs excluded) and indirect
costs with PHiD-CV are estimated at 10% and 12% lower than with the no vaccina-
tion strategy, and 6% and 7 % lower, than with PCV-7. Expected QALY gain from 
vaccination is twofold compared with PCV-7. At price-parity, health beneﬁ ts of vac-
cination can be achieved with a “low cost” per QALY (€10, 000) compared with no
vaccination and the estimated mean differences in cost and QALYs indicate that PHiD-
CV dominates PCV-7. PHiD-CV was predicted to prevent 18,000 more antibiotic 
prescriptions than PCV-7. Sensitivity analyses show that the results are most sensitive
to changes in parameters related to AOM. CONCLUSIONS: Our preliminary results 
indicate that the health beneﬁ ts of vaccination with PHiD-CV compared with no 
vaccination and PCV-7 can be achieved within a “low cost” per QALY gained, accord-
ing to the Swedish National Board of Health and Welfare’s ranking.
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OBJECTIVES: Texas House Bill 790 resulted in the expansion of the newborn
screening panel from 7 to 27 disorders. The objective of this study was to estimate
the incremental cost-effectiveness of the expanded newborn screening program (27 
disorders) compared to the previous standard screening (7 disorders) in Texas.
METHODS: A Markov model (for a hypothetical cohort of Texas births in 2007)
was constructed to compare life-time costs and QALYs between the expanded
newborn screening and pre-expansion newborn screening. Estimates of costs, proba-
bilities of sequelae, and utilities for disorder categories were obtained from Texas 
statistics, the literature, and expert opinion. A baseline discount rate of 3% was used 
for both costs and QALYs, with a range of 0% to 5%. Analyses were conducted from
a payer’s perspective, so only direct medical cost estimates were included. RESULTS:
The life-time incremental cost-effectiveness ratio (ICER) for expanded versus pre-
expansion screening was about $11,000/QALY. Probabilistic sensitivity analysis using
key variables showed that results ranged from about $9,500 to $13,000 /QALY. This 
range is well below the commonly cited willingness to pay threshold of $50,000/QALY. 
CONCLUSIONS: Expanded newborn screening does result in additional expense to 
the payer but also improves patient outcomes by preventing avoidable morbidity and
mortality. The screened population beneﬁ ts from greater QALYs as compared to the 
unscreened population. Overall, expanded newborn screening in Texas was estimated 
to be a cost-effective option as compared to unexpanded newborn screening.
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OBJECTIVES: Recent estimates of cost of otitis media (OM) among children in the 
United States are not available. The objective of this study was to estimate the incre-
mental direct medical expenditures of treating OM among children in the United
States. METHODS: Retrospective analysis was conducted using the 2005 Medical 
Expenditure Panel Survey (MEPS) data. Among all children (age  18 years; n  9691), 
children with OM were identiﬁ ed using International Classiﬁ cation of Diseases (ICD)-
9 diagnosis codes 381 or 382 for OM. Incremental total expenditures associated with
OM was estimated using a regression model adjusting for age, gender, race, ethnicity,
education, geographic region, insurance status and number of medications used (proxy
for comorbidity). Given the skewed distribution of expenditure variables, multiple 
model speciﬁ cations including ordinary least squares regression, generalized linear 
model (GLM) with Poisson, gamma and negative binomial variance functions were 
evaluated. RESULTS: The prevalence of OM among children in the US was estimated
at 11.08%, i.e., 8.15 million persons (95% CI: 10.28% to 11.94%). A majority of 
children with OM were male (52.3%), white (85.7%), and insured (97.3%) with mean 
age of 5.2 o 0.16 years and education of 1.0 o 0.09 years. In unadjusted analysis 
among patients with OM, inpatient visits was the largest proportion of the total
expenditures at $708.97 (SE: $384.25), followed by physician ofﬁ ce visits at $646.35
(SE: 48.07), outpatient visits at $370.88 (SE: $167.97), and prescription medications 
at $348.39 (SE: $122.26). After controlling for covariates, children with OM had
25% higher total expenditures than those without OM (Estimate: 1.25; p  0.024). 
The annual adjusted mean incremental total expenditure associated with OM was 
$245.6 (SE: $117.4; p  0.036) per person. CONCLUSIONS: Given the prevalence
of OM in children and its associated incremental expenditures, the annual direct
medical expenditure for treating OM in children is estimated at approximately $2 
billion in 2007 US dollars.
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OBJECTIVES: To describe the drivers of health care costs among commercially
insured women in the United States with a diagnosis of Hypoactive Sexual Desire 
Disorder (HSDD). METHODS: The Thomson Reuters Marketscan Claims Database
was used to identify women aged 18–64 who received a diagnosis of HSDD from 
january 1, 1998-September 30, 2006. A control group of women with no indication
of any sexual dysfunction was matched 3:1 to HSDD cases based on age, health plan 
and enrollment period. Controls were assigned the index date of their matched case.
Total health care expenditures were evaluated for the one-year prior to and following
the index date and were categorized by type of service (inpatient, outpatient medical, 
outpatient other, prescription). Outpatient medical services included ofﬁ ce visits, labo-
ratory and outpatient procedures; radiology and behavioral health services were cate-
gorized as “outpatient other”. RESULTS: A total of 2870 women were coded with 
an HSDD diagnosis and matched to 8610 controls. In the year prior to index, the 
HSDD group incurred total health care costs that were $1146 higher (p  0.001); in 
